Summary of Key Points Core Viewpoint - The company announced that several executives, including the director Dai Ya and vice general managers Zhang Shengquan and Lou Yanjun, along with the secretary Hu Kangkang, have collectively reduced their holdings by 102,900 shares, representing 0.0675% of the total share capital between December 26 and December 31, 2025 [1] Group 1: Share Reduction Details - Dai Ya reduced his holdings by 24,420 shares [1] - Zhang Shengquan and Lou Yanjun each reduced their holdings by 25,530 shares [1] - Hu Kangkang also reduced his holdings by 24,420 shares [1] - Financial director Pan Aijuan reduced her holdings by 3,000 shares at an average price of 22.06 yuan per share [1] - Pan Aijuan has terminated the remaining plan to reduce 21,420 shares [1]

最新公告列表 近日，辰欣药业发布公告称，公司及控股子公司拟使用不超过29亿元的闲置自有资金进行委托理财及证 券投资，其中委托理财额度不超过23亿元，证券投资额度不超过6亿元，使用期限为董事会审议通过之 日起12个月，资金可滚动使用。投资范围包括银行理财产品、收益凭证、基金、国债、债券、ETF、股 票等。该事项已由公司第五届董事会第十一次会议审议通过，无需提交股东会审议。公司表示将加强风 险控制，防范市场、流动性等风险，并按规定披露相关进展。 截至2026年1月5日收盘，辰欣药业（603367）报收于18.21元，较前一交易日上涨5.14%，最新总市值为 82.45亿元。该股当日开盘17.42元，最高18.25元，最低17.42元，成交额达3.67亿元，换手率为4.52%。 《第五届董事会第十一次会议决议【签字盖章】》 《辰欣药业股份有限公司第五届董事会第十一次会议决议公告》 《辰欣药业股份有限公司关于公司及控股子公司使用闲置自有资金进行委托理财及证券投资的公 告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - Chenxin Pharmaceutical (603367) announced plans to utilize idle funds for entrusted wealth management and securities investment, with a total amount not exceeding 2.9 billion yuan, aiming to enhance the efficiency of fund usage and generate higher returns for shareholders [1] Group 1: Investment Plans - The company and its subsidiaries plan to use idle self-owned funds for entrusted wealth management and securities investment, with a total limit of 2.9 billion yuan, including up to 2.3 billion yuan for entrusted wealth management and up to 600 million yuan for securities investment [1] - The investment aims to improve the efficiency of idle funds while ensuring that the company's main business operations and daily capital needs are not affected [1] Group 2: Investment Types - Entrusted wealth management will primarily involve bank wealth management products, income certificates, and funds from financial institutions [1] - Securities investment will focus on government bonds or reverse repos, bonds, ETFs, stocks, and other investments permitted by laws and regulations [1]

Group 1 - The chemical pharmaceutical sector increased by 3.63% on January 5, with Frontier Biotech leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] - Notable stock performances included Frontier Biotech with a closing price of 21.20, up 17.45%, and Beilu Pharmaceutical at 66.8, up 13.22% [1] Group 2 - The chemical pharmaceutical sector saw a net inflow of 716 million yuan from institutional investors, while retail investors contributed a net inflow of 131 million yuan [2] - Major stocks with significant net inflows included Heng Rui Pharmaceutical with 17.4 million yuan and ST Renfu with 9.15 million yuan [3] - Conversely, stocks like ST Jinfeng and Kangzhiyue experienced net outflows of 6.90 million yuan and 11.61 million yuan respectively [2][3]

（记者 王晓波） 每经头条（nbdtoutiao）——秒光！1499元飞天茅台上线即空，i茅台App冲上苹果购物榜第一，10万用 户已下单！经销商同价做回馈，1000箱很快卖完 每经AI快讯，海思科1月5日晚间发布公告称，公司第五届第三十三次董事会会议于2026年1月5日以通 讯表决方式召开。会议审议了《关于注销控股子公司暨关联交易的议案》等文件。 ...

（记者 王晓波） 每经AI快讯，普洛药业1月5日晚间发布公告称，截至2025年12月31日，公司通过回购专用证券账户以 集中竞价方式回购公司股份2037万股，占公司目前总股本的1.76%，最高成交价为16.85元/股，最低成 交价为15.71元/股，成交总金额约为3.32亿元。 每经头条（nbdtoutiao）——秒光！1499元飞天茅台上线即空，i茅台App冲上苹果购物榜第一，10万用 户已下单！经销商同价做回馈，1000箱很快卖完 ...

格隆汇1月5日丨富祥药业(300497.SZ)在投资者互动平台表示，公司具备生产99.99%和99.999%纯度VC 产品的能力，可根据客户订单要求进行生产。目前产能利用率良好。 ...

Core Viewpoint - Fujilay's stock price has shown a slight increase of 2.00% since the beginning of the year, with a current market capitalization of 3.039 billion yuan, indicating a stable performance in the pharmaceutical sector [1]. Group 1: Stock Performance - As of January 5, Fujilay's stock price reached 33.15 yuan per share, with a trading volume of 14.8913 million yuan and a turnover rate of 0.51% [1]. - The stock has experienced a 0.45% decline over the past five trading days, a 2.16% increase over the last 20 days, and a 1.37% decline over the past 60 days [1]. Group 2: Company Overview - Fujilay Pharmaceutical Co., Ltd. was established on November 27, 2000, and went public on March 29, 2022. The company is located in Changshu, Jiangsu Province [1]. - The main business activities include the research, production, and sales of active pharmaceutical ingredients (APIs) and health product raw materials [1]. - The revenue composition is as follows: 66.02% from lipoic acid products, 14.86% from carnosine products, 11.88% from etoricoxib, 5.95% from phosphatidylcholine products, and 1.29% from other supplements [1]. Group 3: Financial Performance - For the period from January to September 2025, Fujilay achieved an operating income of 323 million yuan, representing a year-on-year growth of 3.23%. The net profit attributable to the parent company was 73.3966 million yuan, showing a significant increase of 430.16% [1]. - Since its A-share listing, Fujilay has distributed a total of 153 million yuan in dividends, with 116 million yuan distributed over the past three years [2]. Group 4: Shareholder Information - As of December 19, 2025, the number of Fujilay's shareholders was 9,810, a slight decrease of 0.01% from the previous period, with an average of 9,079 circulating shares per person, which increased by 0.01% [1]. - As of September 30, 2025, the ninth largest circulating shareholder is Galaxy Kangle Stock A, holding 178,100 shares as a new shareholder [2].

Group 1 - Yifan Pharmaceutical's stock increased by 5.1%, reaching 12.57 CNY per share, with a trading volume of 204 million CNY and a turnover rate of 1.96%, resulting in a total market capitalization of 15.29 billion CNY [1] - The company, established on November 10, 2000, and listed on July 13, 2004, is located in Lin'an District, Hangzhou, Zhejiang Province, and primarily engages in the production and sale of active pharmaceutical ingredients and high polymer materials [1] - The revenue composition of Yifan Pharmaceutical includes self-owned pharmaceutical products (including imports) at 75.52%, vitamins at 11.47%, other pharmaceutical products at 9.52%, high polymer materials at 3.00%, and pharmaceutical services at 0.49% [1] Group 2 - Jin Yuan Shun An Fund has a significant holding in Yifan Pharmaceutical, with the Jin Yuan Shun An Baoshi Dynamic Mixed Fund (620001) holding 112,000 shares, accounting for 3.48% of the fund's net value, making it the eighth largest holding [2] - The Jin Yuan Shun An Baoshi Dynamic Mixed Fund was established on August 15, 2007, with a latest scale of 44.6294 million CNY, achieving a year-to-date return of 11.82% and a one-year return of 11.82%, ranking 5551 out of 8155 in its category [2] Group 3 - The fund manager of Jin Yuan Shun An Baoshi Dynamic Mixed Fund is Kong Xiangpeng, who has been in the position for 8 years and 194 days, with a total fund asset size of 14.3 million CNY, and has experienced a best return of -1.71% and a worst return of -11.58% during his tenure [3] - Co-manager Shang Changceng has been in the role for 2 years and 72 days, managing assets of 44.6291 million CNY, with a best return of 14.04% and a worst return of 0.05% during his tenure [3]

Group 1 - The core point of the news is that Haixiang Pharmaceutical experienced a stock price increase of 5.77%, reaching 6.60 CNY per share, with a trading volume of 1.05 billion CNY and a turnover rate of 1.01%, resulting in a total market capitalization of 10.684 billion CNY [1] - Haixiang Pharmaceutical, established on May 7, 1998, and listed on December 26, 2006, is located in Taizhou, Zhejiang Province. The company specializes in the production and sales of fine chemicals (intermediates for active pharmaceutical ingredients) and specialty active pharmaceutical ingredients, including antibiotics, antiviral drugs, cardiovascular drugs, antiparasitics, and hypoglycemic agents [1] - The revenue composition of Haixiang Pharmaceutical includes 56.07% from active pharmaceutical ingredients and intermediates, 33.09% from dyes and dye intermediates, 9.34% from contract customization services, 1.02% from other sources, and 0.49% from formulations [1] Group 2 - From the perspective of Haixiang Pharmaceutical's top ten circulating shareholders, Southern Fund's Southern CSI 1000 ETF (512100) reduced its holdings by 170,300 shares in the third quarter, now holding 10.3583 million shares, which accounts for 0.64% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a current scale of 76.63 billion CNY. It has achieved a year-to-date return of 29.23%, ranking 1828 out of 4189 in its category [2]